Table 6

Multivariate analysis
Overall survival
Model 1 Model 2 Model 3
HR (95%CI) p= HR (95%CI) p= HR (95%CI) p=
PSA,ng/ml
≤10ng/ml 1.0 1.0 1.0
>10ng/ml 0.49 (0.13-1.83) 0.3 0.45 (0.12-1.74) 0.2 0.45 (0.12-1.74) 0.2
Extra-prostatic extension
Yes 1.0 1.0 1.0
No 3.34 (0.71-15.66) 0.1 3.75 (0.79-17.88) 0.1 3.52 (0.74-16.77) 0.1
Pelvic nodes involved
N0 1.0 1.0 1.0
N+ 1.72 (0.50-5.88) 0.4 1.45 (0.43-4.93) 0.5 1.41 (0.41-4.79) 0.6
Surgical margins involved
No 1.0 1.0 1.0
Yes 1.42 (0.46-4.38) 0.5 1.36 (0.46-3.99) 0.6 1.31 (0.44-3.89) 0.6
Seminal vesicles involved
No 1.0 1.0 1.0
Yes 1.41 (0.50-3.97) 0.5 1.06 (0.37-3.05) 0.9 1.12 (0.38-3.20) 0.8
Gleason score
<7 1.0
≥7 2.19 (0.56-8.62) 0.3
Gleason score
≤7 1.0
>7 2.75 (0.90-8.42) 0.08
Gleason score
<7 1.0 0.2
=7 1.49 (0.33-6.81) 0.6
>7 3.56 (0.78-16.20) 0.1
Stromal -Epithelial IRS Score
=12/≤2 1.0 0.01 1.0 0.01 1.0 0.01
<12/≤2 0.13 (0.04-0.44) 0.001 0.14 (0.04-0.46) 0.001 0.14 (0.04-0.45) 0.001
=12/>2 0.19 (0.02-1.37) 0.1 0.21 (0.03-1.58) 0.1 0.20 (0.02-1.53) 0.1
<12/>2 0.12 (0.01-1.32) 0.08 0.12 (0.01-1.43) 0.09 0.11 (0.01-1.37) 0.09

Abbreviations:HR,Hazard Ratio;CI ,Confidence Interval; PSA, Prostate-specific antigen;IRS,Immuno-reactive score.

Nuzzo et al.

Nuzzo et al. BMC Cancer 2012 12:625   doi:10.1186/1471-2407-12-625

Open Data